Coronary artery disease, "stable" or chronic?
DOI:
https://doi.org/10.5281/zenodo.7844108Keywords:
coronary artery disease, multidisciplinary intervention, cardiovascular medicineAbstract
Letter to the editor that highlights the importance of recognizing stable coronary artery disease, as an entity to which more prominence should be attributed given the chronic repercussions on the prognosis that developing this condition implies.
Downloads
Download data is not yet available.
References
1. Fox KAA, Metra M, Morais J, Atar D. The myth of ‘stable’ coronary artery disease. Nat Rev Cardiol [Internet]. 2020 [citado 20 Dic 2022]; 17(1):9-21. Disponible en: https://www.nature.com/articles/s41569-019-0233-y
2. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A Prospective Natural-History Study of Coronary Atherosclerosis. N Engl J Med [Internet]. 2011 [citado 20 Dic 2022]; 364(3):226-35. DOI: https://doi.org/10.1056/nejmoa1002358
3. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med [Internet]. 2015 [citado 20 Dic 2022]; 372(25):2387-97. DOI: https://doi.org/10.1056/nejmoa1410489
4. Katritsis DG, et al. Guía ESC 2019 sobre el tratamiento de pacientes con taquicardia supraventricular. Rev Esp Cardiol [Internet]. 2020 Jun [citado 20 Dic 2022]; 73(6):496.e1-496.e60. DOI: https://doi.org/10.1016/j.recesp.2019.12.029
5. Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, et al. Angina and future cardiovascular events in stable patients with coronary artery disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Am Heart Assoc [Internet]. 2016 [citado 20 Dic 2022]; 5(10). DOI: https://doi.org/10.1161/JAHA.116.004080
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med [Internet]. 2015 [citado 20 Dic 2022]; 373(22):17-28. DOI: https://doi.org/10.1056/nejmoa1504720
7. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med [Internet]. 2016 [citado 20 Dic 2022]; 375(4):311-22. DOI: https://doi.org/10.1056/nejmoa1603827
8. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med [Internet]. 2016 [citado 20 Dic 2022]; 375(19):1834-1844. Disponible en: https://doi.org/10.1056/nejmoa1607141
2. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A Prospective Natural-History Study of Coronary Atherosclerosis. N Engl J Med [Internet]. 2011 [citado 20 Dic 2022]; 364(3):226-35. DOI: https://doi.org/10.1056/nejmoa1002358
3. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med [Internet]. 2015 [citado 20 Dic 2022]; 372(25):2387-97. DOI: https://doi.org/10.1056/nejmoa1410489
4. Katritsis DG, et al. Guía ESC 2019 sobre el tratamiento de pacientes con taquicardia supraventricular. Rev Esp Cardiol [Internet]. 2020 Jun [citado 20 Dic 2022]; 73(6):496.e1-496.e60. DOI: https://doi.org/10.1016/j.recesp.2019.12.029
5. Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, et al. Angina and future cardiovascular events in stable patients with coronary artery disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Am Heart Assoc [Internet]. 2016 [citado 20 Dic 2022]; 5(10). DOI: https://doi.org/10.1161/JAHA.116.004080
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med [Internet]. 2015 [citado 20 Dic 2022]; 373(22):17-28. DOI: https://doi.org/10.1056/nejmoa1504720
7. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med [Internet]. 2016 [citado 20 Dic 2022]; 375(4):311-22. DOI: https://doi.org/10.1056/nejmoa1603827
8. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med [Internet]. 2016 [citado 20 Dic 2022]; 375(19):1834-1844. Disponible en: https://doi.org/10.1056/nejmoa1607141
Downloads
Published
2023-04-19
How to Cite
1.
Serna-Trejos JS, Lenis-González JP, Bermudez-Moyano SG. Coronary artery disease, "stable" or chronic?. Rev Inf Cient [Internet]. 2023 Apr. 19 [cited 2025 Apr. 2];102:4108. Available from: https://revinfcientifica.sld.cu/index.php/ric/article/view/4108
Issue
Section
Letter to Editor
